Article
Bioinformatics-based analysis of TCGA to identify the prognostic biomarkers in HR-positive/HER2-negative tamoxifen-treated breast cancer
2019-09-12
Abstract excerpt
<title>Abstract</title> <p>Background Patients with hormone receptor-positive (HR+) breast cancer, which accounts for approximately 70% of all breast cancers, receive tamoxifen therapy to inhibit recurrence and improve overall survival. However, the cumulative risk of distant recurrence in the past 20 years is still as high as 22 to 52% after 5 years of endotherapy. TNM stage, histological grade and age are impor...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c95b3c63-2ae1-50a3-9dc8-b39f804105b4
- DOI
- 10.21203/rs.2.14316/v1
